Incannex is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for patients living with chronic diseases and significant unmet needs. Our lead candidates are currently in Phase 2/3 and Phase 2 clinical development.
Obstructive Sleep Apnea
RePOSA
Ph 2/3 Safety and Efficacy Trial
- 560-patient, randomized, double-blind safety and efficacy study
- Dosing started May 2024
BABE
Bioavailability Trial
- 115-subject, bioavailability and bioequivalence study
- Dosing completed July 2024
POC
Ph 2 Trial
- Crossover, safety and efficacy study
- Study completed
Generalized Anxiety Disorder
PsiGAD2
Ph 2 Dose Comparison
- 94-patient, double-blind, safety and efficacy study
- Dosing expected to begin 1H 2025
PsiGAD1
Ph 2 Trial
- 73-patient, double-blind, safety and efficacy study
- Dosing completed January 2024
Rheumatoid Arthritis
Phase 2
Ph 2 Safety and Efficacy Study
- 128-patient, double-blind, safety and efficacy study
- Dosing started January 2024
Phase 1
Ph 1 Safety and PK Study
- 36-patient, Phase 1 safety and PK study
- Study completed
Subscribe and stay connected
"*" indicates required fields